Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster discussion session - Immunotherapy of cancer 1

5678 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Date

20 Oct 2018

Session

Poster discussion session - Immunotherapy of cancer 1

Topics

Clinical Research;  Immunotherapy

Tumour Site

Urothelial Cancers

Presenters

Charles Rudin

Authors

C.M. Rudin1, H.S. Pandha2, S. Gupta3, M.R. Zibelman4, W. Akerley5, D. Day6, A.G. Hill7, R.E. Sanborn8, S.J. O'Day9, T.D. Clay10, G.M. Wright11, R. Jennens12, D.E. Gerber13, J.E. Rosenberg1, C. Ralph14, D.C. Campbell15, B.D. Curti8, E.V. Schmidt16, M. Grose17, D. Shafren17

Author affiliations

  • 1 Medical Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2 Dept. Of Microbial & Cellular Sciences, Royal Surrey County Hospital, GU27WG - Surrey/GB
  • 3 Oncology, Huntsman Cancer Institute, Salt Lake City/US
  • 4 Medical Oncology, Fox Chase Cancer Center, 19111 - Philadelphia/US
  • 5 Oncology, Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 6 Medical Oncology, Monash Health, 3168 - Melbourne/AU
  • 7 Medical Oncology, Tasman Oncology Research, 42116 - Southport/AU
  • 8 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland/US
  • 9 Medical Oncology, John Wayne Cancer Institute, 90404 - Santa Monica/US
  • 10 Medical Oncology, St. John of God, 6008 - Subiaco/AU
  • 11 Medical Oncology, St. Vincent's Hospital Melbourne, 3065 - Fitzroy/AU
  • 12 Medical Oncology, Epworth Healthcare, 3121 - Richmond/AU
  • 13 Medical Oncology, UT Southwestern, 75390 - Dallas/US
  • 14 Medical Oncology, St. James University Hospital, L797TF - Leeds/GB
  • 15 Medical Oncology, Barwon Health Hospital, 3220 - Geelong/AU
  • 16 Oncology, Merck Research Laboratories, 19454 - North Wales/US
  • 17 Oncology, Viralytics, Limited, 2000 - Sydney/AU
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5678

Background

Coxsackievirus A21 (CVA21, CAVATAK) is a naturally occurring ICAM-1 targeted oncolytic immunotherapeutic virus. Pembrolizumab (pembro) is a human programmed death receptor-1 (PD-1) blocking mAb. Active CVA21 replication mediates a cellular RIG-I response increasing levels of immune-checkpoint (CPK) molecules namely PD-L1 and immune-cell infiltration in the tumor microenvironment of treated human melanoma and bladder cancer lesions. IV delivery of CVA21 results in tumor targeting evidenced by detection of CVA21 viral RNA in tumor biopsies at study Day 8. The combination of IV CVA21+pembro may provide combinatorial benefit in the clinic.

Methods

KEYNOTE-200 is an on-going Phase Ib study with primary objectives to assess the safety and preliminary efficacy of IV CVA21 + pembro. Secondary objectives are to assess ORR by irRECIST, PFS, and OS. In the expansion cohort, 78 pts were given IV CVA21 + pembro, with IV CVA21 dose 1x109 TCID50 on study days 1, 3, 5, 8, 29 and Q3W for 6 additional infusions. Pembro was given at 200 mg IV Q3W from Day 8 for up to 2 years.

Results

The combination of IV CVA21 and pembro was generally well tolerated with no DLT’s and 12.8% (10/78 pts) G3 TRAE’s. No G4/5 TRAE’s have been observed. The ORR in evaluable CKP naïve NSCLC pts is currently 23% (7/31, 2CR+5PR) and 33% (7/21) in pts not harbouring EGFR or ALK mutations. In CPK naïve bladder cancer pts, most of whom were second line, the ORR is 31% (8/26, 3CR+5PR). Of note, was an ORR of 30% (3/10) in CPK naïve bladder cancer pts with neg PD-L1 tumor staining at baseline. Preliminary IHC staining of paired biopsies from evaluable CPK naïve pts with neg/low baseline PD-L1 revealed a notable increase in PD-L1+ tumor cells at Day 15 of 62% (8/13) of pts following treatment with CVA21 and pembro. The current median OS for CPK naïve NSCLC and bladder cancer pts is 9.5 and 11.2 mos, respectively. Prolonged SD was the best ORR observed in pts previously treated with CKP (n=17).

Conclusions

Systemic CVA21 with pembro has been well tolerated and has mediated encouraging clinical signals of activity in parallel with notable increases in PD-L1 tumor levels within these pt populations.

Clinical trial identification

NCT02043665

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.